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Abstract—Adipose tissue inflammationmediates the association between excessive body fat accumulation
and several chronic inflammatory diseases. A high prevalence of obesity-associated adipose tissue inflam-
mation was observed not only in patients with cardiovascular conditions but also in patients with inflam-
matory bowel diseases, abdominal aortic aneurysm, or cardiorenal syndrome. In addition to excessive ca-
loric intake, other triggers promote visceral adipose tissue inflammation followed by chronic, low-grade
systemic inflammation. The infiltration and accumulation of immune cells in the inflamed and hypertrop-
hied adipose tissue promote the production of inflammatory cytokines, contributing to target organ dam-
ages. This comorbidity seems to delimit subgroups of individuals with systemic adipose tissue inflamma-
tion and more severe chronic inflammatory diseases that are refractory to conventional treatment. This re-
view highlights the association between adipose tissue immune response and the pathophysiology of vis-
ceral adiposity-related chronic inflammatory diseases, while suggesting several new therapeutic strategies.
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INTRODUCTION
Excessive body fat is a chronic inflammatory disorder
that affects people of all ages and ethnicities. Worldwide,
illnesses related to excess adipose tissue have emerged as
the leading causes of cardiovascular mortality [1]. Obese
individuals have higher prevalence of hypertension, dia-
stolic dysfunction, left ventricular hypertrophy, increased
arterial stiffness, and arterial calcification compared to
normal weight individuals [2, 3]. In overweight and obese
children, hemodynamic alterations and abnormal metabol-
ic parameters can be present even at very young age and
are silently working their way toward chronic inflammato-
ry diseases [4–8]. Moreover, the increased periorgan fat
mass can have direct functional and mechanical roles con-
tributing to the subclinical organ damage by exerting local
toxic effects [9, 10]. In the general population, excessive
adipose tissue is associated with high incidence of nonal-
coholic fatty liver disease (NAFLD) [11], chronic kidney
disease [12], and end-stage renal failure [13]. Adipose
tissue immune response to various triggers is different
based on anatomical location. Visceral adipose tissue mass
is a major determinant of endothelial dysfunction, liver
steatosis, plasma level of adiponectin, atherosclerosis, and
metabolic syndrome [14]. Importantly, inflammation ap-
pears to be a common denominator for all of these abnor-
mal metabolic conditions [15].
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Adipose tissue is an organ enriched in macrophages
and capable of generating and sustaining a strong inflam-
matory response to noxious triggers by involving both the
adipocytes and the vascular stroma fraction (25 and 75 %
of the adipose tissue cell population, respectively) [16].
Several mechanisms are involved in adipocyte inflamma-
tion: (1) adipocyte stress response (hypertrophy, hypoxia,
and endoplasmic reticulum stress), (2) altered adipokine
secretion, and (3) adoption of a macrophage-like pheno-
type. These events are interrelated and can sustain each
other. Adipocyte hypertrophy has been shown to be caus-
ally linked with inflammation and systemic insulin resis-
tance. Increased adipocyte size changes the adipocyte
membrane capacity to adapt to adipose tissue expansion,
potentially leading to higher vulnerability to inflammation
[17]. In obese Zucker rats, adipocyte hypertrophy is
followed by a proportional increase in the adipocyte lipid
droplet size and a higher concentration of caveolin-1 onto
each lipid droplet surface. The caveolin-1-dependent en-
dothelium pathway has been shown to participate in the
control of macrophage extravasation from the blood into
the adipose tissue [18]. This inflammatory milieu triggers
intrinsic inflammatorymolecules like tumor necrosis factor
alpha (TNF-α), which can either sustain a macrophage-like
phenotype in undifferentiated precursor cells [19] or di-
minish the ability of mature adipocytes to further expand
and store lipids, thus sustaining an already “vicious cycle”
(Fig. 1). Other proinflammatory chemokines, such as
monocyte chemoattractant protein-1 (MCP-1/CCL2) and
its receptor (CC chemokine receptor 2 (CCR2)), are highly
expressed on hypertrophied adipocytes and can accelerate
the migration of the bonemarrow-derivedmonocytes/mac-
rophages and their adipose tissue homing [20]. Autocrine
and paracrine regulatory loops involving angiotensin and
adiponectin can further modulate the cross talk between
adipocytes and adipose tissue macrophages [21, 22].
Fig. 1. Obesity-induced visceral fat inflammation promotes end-organ chronic inflammatory damage. Obesity-related adipose cell dysfunction triggers
migration of innate and adaptive immune effector cells. Activation of immune system and adipose cell dysfunction promotes an inflammatory milieu cha-
racteristic to obesity-related pathologic states. Chronic production of TNF-α, IL-6, and MCP-1 and an increased ratio of angiotensin II to adiponectin ma-
intain a vicious pathologic cycle that culminates in organ damage. Accumulation of dioxin-like environmental toxicants (AhR ligands) in adipose tissue
amplifies diet-related adipocyte hypertrophy (as seen in abdominal aortic aneurysm, inflammatory bowel diseases or cardiorenal syndrome).
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Senescence, necrosis, and adipocyte death are associated
with increased macrophage infiltration in the expanded
adipose tissue (Fig. 1).
Differential activation of adipose tissue macrophages
modulates the amplitude of adipose tissue inflammation.
Depending on the types of stimuli, macrophages respond
with either classic proinflammatory (M1) or alternative
anti-inflammatory (M2) activation. Under normal physio-
logic circumstances, the adipose tissue-resident macro-
phages exhibit an alternatively activated, reparative, or
M2 phenotype. Enlarged and dysfunctional adipocytes
favor and sustain the activation of classic proinflammatory
macrophages or the M1 phenotype [23] that will further
arrest the recruitment of healthy, small fat cell progenitors.
In time, and due to a limited vascular supply, the
hypertrophied mature adipocytes will become fibrotic
and drive subclinical inflammation toward chronic
irreversibility [24].
ADIPONECTIN AND ANGIOTENSIN CROSS
TALK IN ADIPOSE TISSUE INFLAMMATION
Adipose tissue produces several adipokines with im-
portant roles in adipose tissue metabolism, inflammation,
as well as systemic effects on other organs [25].
Adiponectin is the main anti-inflammatory mediator pro-
duced in adipose tissue [26]. Human adiponectin gene
contains a signal sequence, a collagen-like domain, and a
globular domain similar to the complement factor C1q.
Biological effects of adiponectin depend upon the forma-
tion of multimeric complexes. The basic unit is a trimer,
which can associate through disulfide bonds to generate
hexamers and dodecamers referred to as low, medium, and
high molecular weight adiponectin (LMW, MMW,
HMW), respectively. Cleavage of the adiponectin mole-
cule by leukocyte esterase can release the globular part,
which retains biological activity. It is important to distin-
guish between these isoforms since they may have oppos-
ing effects on inflammation [27, 28]. Both proinflammato-
ry and anti-inflammatory effects have been described for
all forms of adiponectin. This is in part explained by the
experimental conditions and cell type, although lipopoly-
saccharide (LPS) contamination is another important fac-
tor. Recent studies suggest that HMW adiponectin is the
main anti-inflammatory moiety. In vitro experiments have
shown that globular adiponectin induces nuclear factor
kappa B (NF-kB) and proinflammatory cytokines, but
prolonged exposure blocks further activation. In contrast,
HMW adiponectin can quickly prevent NF-kB activation.
Adiponectin production is regulated at transcriptional
and posttranslational levels [29]. During adipogenesis,
several transcription factors, including peroxisome
proliferator-activated receptor gamma (PPARγ), bind its
promoter to upregulate adiponectin messenger RNA
(mRNA) expression. Plasma level of adiponectin is nega-
tively correlated with body mass index (BMI) and visceral
fat accumulation [30]. Therefore, obese and morbidly
obese patients have low and very low adiponectin levels,
respectively. Weight loss through caloric restriction, exer-
cise, or bariatric surgery increases adiponectin and/or the
ratio of HMW to total adiponectin [31, 32]. In vivo and
in vitro studies suggest that the visceral rather than the
subcutaneous fat is the main source of adiponectin. Impor-
tantly, the size of adipocytes correlates with the amount of
secreted protein. Large, mature, and insulin-insensitive
adipocytes secrete very little adiponectin in comparison
with small, young, and insulin-sensitive preadipocytes.
Isakson et al. isolated fresh, mature adipocytes from obese
individuals and showed that they had an increased expres-
sion of mitogen-activated protein 4 kinase 4 (MAP4K4),
which is known to inhibit peroxisome proliferator-activat-
ed receptor gamma (PPARγ) induction and the recruitment
of new, small insulin-sensitive preadipocytes [19].
Two main adiponectin receptors have been identified,
with homology to G protein-coupled receptors. These re-
ceptors have distinct tissue specificities within the body
and have different affinities to the various forms of
adiponectin (monomers or multimers). Adiponectin binds
to the extracellular –COOH terminus of adiponectin recep-
tors (AdipoR1/AdipoR2) and recruits the adaptor protein
containing pH domain (APPL1) which in turn activates
AMP-activated protein kinase (AMPK) [33]. These mole-
cules also modulate phosphoinositide-3-kinase protein ki-
nase B (PI3K/AKT) and mammalian target of rapamycin
(mTOR) which function as regulatory hubs in both meta-
bolic and immune processes. Signaling cascades that
polarize T cell and macrophage responses incorporate
these molecules [34, 35]. Therefore, adiponectin can
regulate both the acquired and innate arms of the
immune responses.
The renin–angiotensin system (RAS) has been tradi-
tionally associated with systemic blood pressure and renal
electrolyte homeostasis. Mounting evidence shows that
RAS plays an important role in adipose tissue inflamma-
tion [36]. Visceral adipose tissue expresses all the compo-
nents of RAS. Angiotensin II is generated through the
successive cleavage of angiotensinogen by renin and an-
giotensin-converting enzyme (ACE). Engagement of an-
giotensin receptor 1 (AT1r) by angiotensin II can induce
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several T helper-1 (Th1) cytokines leading to vascular
inflammation. Furthermore, AT1r signaling can induce
expression of MCP-1 and CCR2 that promote visceral
adipose tissue inflammation and vascular endothelial dam-
age [37]. It is clear now that obesity is associated with
activation of RAS and decreased production of adiponectin
[38]. In fact, evidence point toward RAS overactivation in
obesity and the possibility that RAS to be the link between
obesity and insulin resistance. Functionally, angiotensin II
plays a role in energy sensing, as well as modulating fat
mass expansion via its effect on adipogenesis, lipogenesis,
and lipolysis. It is plausible that in a state of acute energy
influx to the adipose tissue, angiotensinogen production
leads to increased local angiotensin II levels, which in turn
induces local vasoconstriction and lower lipolytic rates.
Conversely, in fasting conditions, due to lower local an-
giotensin II levels, vasodilatation occurs, leading to in-
creased rates of lipolysis. Taken together, the net paracrine
effect of angiotensin II is to reduce lipolysis and promote
lipogenesis, ultimately increasing lipid storage and inflam-
mation in adipose tissue [39]. In turn, blockade of the RAS
system can increase the anti-inflammatory adipokine
adiponectin [40] and modify the relative balance of these
two adipokines, effect that could potentially lessen visceral
fat inflammation.
ADIPOSE TISSUE IMMUNE RESPONSE
Expansion of adipose tissue is accompanied by chron-
ic low-grade inflammation that primes target organs for the
development of obesity-associated chronic inflammatory
diseases. Adipose tissue-resident immune cells play a ma-
jor role in the induction and regulation of obesity-induced
systemic inflammation. These can be proinflammatory
immune cells (e.g., neutrophils, dendritic cells, M1 macro-
phages, Th1 cells, B cells, and mast cells) as well as anti-
inflammatory immune cells (e.g., regulatory T cells, Th2
cells, M2 macrophages, and eosinophils). Although most
types of immune cells are already present in the adipose
tissue, their number increases dramatically with the pro-
gression of obesity.
Granulocytes in Adipose Tissue Inflammation
Neutrophils present fundamental mechanisms of ef-
fector cells (e.g., opsonization, agglutination, complement
activation, regulation of inflammation) and participate in
initiation of immune response and resolution of inflamma-
tion. Low circulating adiponectin level characteristic to
obesity was shown to induce neutrophil activity and num-
ber in the peripheral blood [41]. Activated neutrophils
infiltrate adipose tissue early during diet-induced obesity
in mice in an attempt to limit the local inflammatory
process [42]. Moreover, in vitro studies have shown that
neutrophils physically bind adipocytes in a CD11b/ICAM-
1 interaction and in a manner dependent on their activation
state [42]. A recent study evidenced that diet-induced
obesity in mice determined a rapid increase in adipose
tissue’s neutrophil presence, lasting up to 90 days, and a
parallel increased expression in the activity of neutrophil
elastase [42]. Neutrophil elastase seemed to influence the
following macrophage infiltration and M1 polarization,
since M2 (alternatively polarized) macrophages were prev-
alent in obese mice lacking this enzyme [43].
Mast cells are important sensors of acute inflam-
mation triggered by pathogenic bacteria and also play
an important part in allergic type reactions [44].
More recent evidence implicates these cells in car-
diometabolic diseases [45]. Ironically, when Paul
Ehrlich described them in 1878, he coined them
“Mastzellen” or “fattening” cells based on their gran-
ule-enriched cytoplasm. Mast cells share a common
bone marrow precursor with basophil granulocyte.
Both cell types respond to IgE stimulation following
an allergen encounter, and they release similar medi-
ators responsible for local and systemic anaphylactic
reaction [46, 47]. As opposed to basophils, mast cells
leave the bone marrow in an immature state and then
fully differentiate in specific tissue sites. Thus, mast
cells display tissue specificity and are more intimate-
ly related to specific homeostatic and pathologic
states. Mast cells respond to microenvironment by
releasing preformed contents of granules (histamine,
heparin, tryptase, and chymase) or de novo synthesis
of proinflammatory cytokines such as IL-6, IL-8, and
TNF-α. Based on protease content, we distinguish
either tryptase or tryptase/chymase-expressing mast
cells. In terms of localization, mast cells are found
in two main compartments: mucosal surfaces and
perivascular connective tissue. Mast cells grow and
proliferate in response to growth factors, stem cell
factor (SCF), and nerve cell growth factor (NGF) as
well as cytokines (IL-3, IL-4, IL-9, IL-10). Abnormal
expansion of visceral adipose tissue is accompanied
by influx of immune cells. Mouse models of diet-
induced obesity showed accumulation of mast cells
in adipose tissue [45, 48, 49]. Mast cell KitW-sh/W-sh-
deficient mice, lacking only mature mast cells, are
resistant to diet-induced obesity and are able to
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maintain glucose homeostasis when fed with a high-
fat diet. Analysis of their visceral adipose tissue
revealed a significant reduction in proinflammatory
cytokines and chemokines [48] and a decrease in
macrophage number. Therefore, it appears that mast
cell arrival in adipose tissue precedes the release of
proinflammatory mediators that attract macrophages.
Furthermore, even the pharmacological inhibition of
mast cell degranulation reproduced the metabolic
phenotype seen in KitW-sh/W-sh-deficient mice.
Human adipose tissue appears to contain both
tryptase and tryptase/chymase-expressing mast cells.
Despite similar representation in both lean and obese
subjects, it appears that mast cells in the latter group
have an increased rate of degranulation [50]. More-
over, obese subjects that progressed to complications
like diabetes were found to have a higher number of
mast cells. Visceral fat mast cells from obese patients
were found to produce significantly higher proinflam-
matory cytokines (IL-1, IL-6) and macrophage
chemoattractant (MCP-1) previously shown to induce
insulin resistance [51, 52]. Adipose tissue fibrosis has
been linked to obesity insulin resistance and abnor-
mal cytokine/adipokine secretion from adipose cells
[45, 53]. Development of obesity in diabetic db/db
mice was associated with recruitment of immature
mast cells and whose maturation paralleled the met-
abolic abnormalities. Mast cell-derived tryptase was
found to promote collagen 5 mRNA expressions in
fibroblasts and was associated to adipose tissue fi-
brosis in db/db mice [45]. Antifibrotic compounds
(tranilast, angiotensin-converting enzyme inhibitors,
and silymarin) coupled with dietary interventions
could prevent mast cell maturation and degranulation
to reduce associated metabolic abnormalities [53].
Recently, the effects of adipose tissue eosino-
phils have also been documented on local macro-
phage activity and polarization. In the adipose tissue,
alternative (M2) activation of macrophages is driven
by the cytokine interleukin-4 (IL-4). Eosinophils are
the major IL-4-expressing cells in white adipose tis-
sues of mice. In their absence, the M2 macrophage
number is greatly attenuated leading to impaired glu-
cose tolerance and insulin resistance [54]. Thus, re-
cent studies suggest that beyond monocytes and mac-
rophages, plenty of other myeloid cells, such as
dendritic cells, lymphoid cells like NK cells, NKT
cells, B and T lymphocytes, and eosinophils, could
play a combined role in the inflammatory process
associated with obesity. Due to the presence of such
an immune cell spectrum, several researchers consid-
er adipose tissue as an ancestral lymphoid organ
where physiologic and pathologic immune processes
can take place simultaneously [55].
Dendritic Cells, Monocytes, and Macrophages
in Adipose Tissue Inflammation
Dendritic cells (DCs) are specialized, heterogeneous
group of mononuclear cells able to acquire, process, and
present antigens to naïve T cells. Based on their phenotype
and functional characteristics, DCs can be found in almost
all tissues and are further divided into the following: con-
ventional/myeloid DCs (CD11+), plasmacytoid DCs
(CD11c−CD303+), and a novel group of inflammatory
DCs (inf-DCs) generated from in situ activation of
monocytes recruited into the site of inflammation.
Several studies consider obesity-induced adipose tissue
hypoxia and elevated level of plasma free fatty acids
(FFAs) as potential initiating events in the activation and
recruitment of DCs into the enlarged adipose tissue.
Bertola et al. [56] showed for the first time the
accumulation of specific inflammatory dendritic cells
CD11chighF4/80low in the adipose tissue of obese mice
and CD11c+CD1c+ in the adipose tissue of obese
patients. The emergence and expansion of CD11chighF4/
80low DCs the in obese mice and CD11c+CD1c+ in the
obese patients induced proinflammatory Th17 cell
responses and macrophage accumulation and correlated
with higher BMI and insulin resistance. Mice lacking
DCs had a reduced number of macrophages in the
adipose tissue, whereas DC replacement in DC−/−mice
increased macrophage populations in the adipose tissue.
Moreover, lean wild-type mice that received bone marrow-
derived DCs had macrophage infiltration in the adipose
tissue, while mice lacking DCs completely were resistant
to the high-fat diet weight gain and metabolic
abnormalities [57]. Importantly, Hagita et al. [58] proved
that adipose tissue location can dictate the degree of
associated vasculature inflammation. In an in vivo study,
they showed that mice that had lean visceral fat
transplanted around the femoral artery presented
increased vascular inflammation (leukocyte and DC
recruitment to the femoral artery) as compared to mice
that had lean subcutaneous fat transplanted around
femoral artery. Moreover, when they are used for
transplantation, the visceral/subcutaneous fat from donor
mice fed with a high-fat diet, the inflammatory response at
the femoral artery level was substantially increased.
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Therefore the effect of high-fat diet on adipocytes is
compartment specific [58].
New studies have shown that in response to high-fat
diet, the hypertrophied adipocytes produce more CCL20, a
chemoattractant whose receptor—CCR6—is highly
expressed on adipose tissue dendritic cells. In addition,
the adipose tissue dendritic cells express higher levels of
IL-6, TGF-β, and IL-23 [59]. These are essential cytokines
for Th17 cell proliferation and differentiation. Co-cultures
of adipose tissue dendritic cells and naïve T cells promoted
proinflammatory Th17 cell differentiation and IL-17 pro-
duction. This effect was significantly increased when com-
pared with dendritic cells derived from spleen [59]. These
studies show that adipose tissue DCs are among the first to
sustain the expanded adipose inflammatory milieu. Fur-
thermore, by recruiting and activating other immune cells,
including monocytes and macrophages, the adipose tissue
DCs propagate the immune response associated with adi-
pose tissue expansion [57].
Monocytes are also heterogeneous for phenotype and
function, and different subsets rise in response to microen-
vironment cues. Two main monocyte subsets may be distin-
guished based on their expression of specific receptors: in
humans CD14 (LPS receptor) and CD16 (FcgammaRIII)
and in mice Ly6C and Gr1. Based on the relative expression
of CCR2 and CX3C chemokine receptor 1 (CX3CR1),
Ly6Chi monocytes are Gr1+CCR2+CX3CR1lo and
correspond to human CD14++CD16− (classical monocytes)
whereas Ly6Clo monocytes are Gr1−CCR2−CX3CR1hi and
correspond to human CD14+CD16+ (nonclassical
monocytes). Circulating nonclassical monocytes
demonstrate a patrolling behavior along blood vessel walls
[60] and form “standby” deposits in noninflamed peripheral
tissues such as spleen, lung, and liver [61].
However, despite the overall conservation, the
comparison of the two species’ subsets highlighted
some diversity such as expression of fatty acid
translocase (FAT/CD36), tetraspanin CD9, triggering
receptor expressed on myeloid cells 1 (Trem-1), and
PPARγ. Recently, Shantsila et al. [62] demonstrated
unequivocally that human monocyte group includes
three major functionally and phenotypically differ-
ent subsets: the classical CD14+CD16−CCR2+, the
intermediate CD14+CD16+CCR2+, and the nonclassical
CD14dimCD16+CCR2− monocytes.
Most of the monocytes are CD14+CD16− and can
amount to up to 85 % in healthy subject [62]. The CD16+
monocytes increase their frequency in response to chronic
inflammatory conditions, such as chronic kidney disease
(CKD) [63], obesi ty [64, 65], and associated
cardiovascular diseases [66]. High levels of the
CD14+CD16+ subset of CD16+ were associated with
cardiovascular events [67] and reduced survival at
35 months in CKD patients [68]. In the same time,
CD14dimCD16+ subtype was positively correlated with
the BMI [65] and atherogenic lipoproteins and inversely
associated with high-density lipoprotein cholesterol.
Poitou and colleagues [69] investigated the frequency
of CD16+ monocyte subsets and their potential role in
obesity and weight loss; they showed an increase in
CD14dimCd16+ monocytes in obese and diabetic patients.
Importantly, weight loss as well as surgery-induced weight
loss caused a reduction of CD14dimCD16+ monocytes that
correlated with reduction of subclinical atherosclerosis, as
evaluated by intima–media thickness.
Obesity promotes the mobilization of monocytes
from the bone marrow in part by activating the CCR2.
Deficiency of CCR2 or its ligand, MCP-1, in mice results
in failure of monocyte mobilization and is associated with
protection from monocyte infiltration into adipose tissue
and insulin resistance [70, 71]; Spite et al. [72] report that
activation of the leukotriene B4 (LTB4) and its receptor
BLT-1 axis is required for obesity-induced increases in
peripheral blood monocytes and subsequent adipose tissue
macrophage accumulation.
Adipose tissue macrophages are the main component
of adipose tissue immune cells (40–60 % of all adipose
tissue immune cells), and their number increases progres-
sively after only 1 week of high-fat diet feeding [73]. Two
major macrophage phenotypes have been described: clas-
sically activated or M1, which trigger a proinflammatory,
type 1 immune response, and alternatively activated orM2,
which promote anti-inflammatory, type 2 responses during
the healing process [74, 75]. However, in vivo, monocytes
and macrophage phenotypes more likely represent points
on a spectrum with high plasticity that shapes obesity-
induced inflammation.
Progressive adipose tissue expansion is accompanied
by macrophage accumulation and decreased expression of
key genes of adipocyte differentiation (PPARγ and
C/EBPα). This reduces the number of new, small adipo-
cyte recruitment and leads to mature adipocyte hypertro-
phy [76]. Nevertheless, there are different rates of macro-
phage accumulation based on the anatomical location of
the adipose tissue (i.e., visceral vs subcutaneous fat). Hu-
man subcutaneous adipose tissue macrophages retrieved
by liposuction from healthy, overweight women are com-
posed mainly of cells expressing CD206, a marker of
activated macrophages. However, it seems that only the
CD206+/CD16+ cells accumulate in the adipose tissue
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directly proportional with adiposity. Although a rapid local
differentiation of inflammatory monocytes into
macrophages cannot be excluded, enhanced local
proliferation might be involved in the accumulation of
CD206+/CD16+ cells.
Significant differences in MCP-1 production and in
the amount of infiltrated macrophages were found in the
subcutaneous, epididymal, renal, and mesenteric fat sam-
ples from obese and control mice. The MCP-1 protein
levels were significantly higher in the obese mice than
those in the nonobese controls, with the highest MCP-1
level detected in the mesenteric adipose tissue sample from
obese mice. Moreover, the differences in MCP-1 level
among anatomically different adipose tissues correlated
with the number of macrophages infiltrated into that fat
pad. These results indicate that the mesenteric adipose
tissue is a major depot for MCP-1, which can modulate
macrophage trafficking and activation during obesity-re-
lated inflammatory diseases [77]. On the other hand, an
experimental study in mice evidenced new players such as
microRNAs (miR-233) that suppress the classic proinflam-
matory (M1) pathways and enhance the alternative anti-
inflammatory (M2) responses in the adipose tissue [78].
Natural Killer Cells and Natural Killer T Cells
in Adipose Tissue Inflammation
Obesity is accompanied by a low-grade, systemic
inflammatory process that involves both innate and adap-
tive immunity.
High-fat diet feeding stimulates the secretion of inter-
feron gamma (IFN-γ) in the adipose tissue of wild-type
mice. Several studies showed that IFN-γ initiates early
accumulation of T and B lymphocytes in the adipose tissue
and activates local macrophage recruitment and their clas-
sical M1 differentiation [79]. In humans, O’Rourke et al.
[80] showed that visceral adipose tissue from obese indi-
viduals presented elevated IFN-γ transcript levels and a
high frequency of macrophages, T cells, and natural killer
(NK) cells relative to subcutaneous adipose tissue. On the
other hand, obese but IFN-γ-deficient mice had signifi-
cantly less adipose tissue expression of inflammatory
genes such as TNF-α and MCP-1 and better glucose tol-
erance than the obese, control mice consuming the same
diet [81].Moreover, the absence of Tand B lymphocytes in
the RAG2−/−mice fed with a high-fat diet had no effect on
the increased macrophage accumulation in the expanded
adipose tissue or insulin resistance [79]. In conclusion, in
the absence of T and B cells, the NK cells are also
able to produce IFN-γ and TNF-α, which are
relevant to macrophage recruitment in the adipose
tissue during obesity.
The early role of natural killer T (NKT) cells and their
regulation in adipose tissue immune response are not yet
thoroughly deciphered. Currently, it is known that NKT
cells can bridge innate and adaptive immune responses
[82]. There are three types of NKT cells: invariant NKT
(iNKT), noninvariant NKT, and NKT-like cells. Invariant
NKT and noninvariant NKT cells are CD1d dependent
[83]. The MHC class I-like CD1d glycoprotein is a mem-
ber of the CD1 family of antigen-presenting molecules and
is responsible for the selection of NKT cells. Importantly,
NKTcell population and CD1d expression was found to be
highly expressed in adipocytes from obese mice and
humans compared to those from lean mice and lean human
subjects [84]. In addition, the CD1d-expressing adipocytes
are able to stimulate NKT cell activity through mere phys-
ical interaction. In animal studies, CD1d(−/−) mice fed with
a high-fat diet gained little weight, had less liver
inflammation, and presented smaller adipocytes in
comparison with wild-type control mice on the same diet
[85]. The NKTcell-deficient Jα18−/−mousemodel fed with
a high-fat diet became more obese and displayed increased
adipose tissue inflammation in the early stage of obesity.
These results underline the role of NKT in the early
adipose tissue inflammation and obesity-related
insulin resistance [73, 84].
T cells in Adipose Tissue Inflammation
Adaptive immunity seems to assign a causative role to
B and T lymphocytes in activating innate immunity [86],
while regulatory T (Treg) cells have a suppressive function,
rescuing obese mice from chronic adipose tissue inflam-
mation [87].
Duffaut et al. [79, 88] observed that fat expresses a
predominant macrophage population with CD3+-activated
T cells (including CD4+ T helper and CD8+ T cytotoxic
cells), a minor number of CD56 NK cells, and few CD19+
B lymphocytes. The CD3+CD56+ NKT cells and CD25+
Treg cells were found in a very low number in steady state.
Interestingly, most CD3+-activated T cells were organized
in clusters surrounding adipocytes, and their number
increased proportionally with the adipose tissue size and
BMI. However, this distribution was influenced by the
degree of obesity and by adipose tissue location. Visceral
adipose tissue from obese patients showed an increased
number of macrophages and lymphocytes, especially
CD8+ effector T cells, compared to subcutaneous fat.
Moreover, proinflammatory chemokines followed a
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similar pattern and increased proportionally to the amount
of visceral adipose tissue [79, 88]. Both CD4+ and CD8+ T
cells have been found in adipose tissue, and their number
increases with obesity [81] in both humans and mice [89].
Depletion of CD8+ cells in obese mice decreased the
number of macrophages in adipose tissue and lowered
TNF-α and IL-6 levels, while T cell receptor (TCR)−/−
mice were clearly protected against obesity-induced
hyperglycemia and insulin resistance [90]. Accordingly,
adoptive transfer of CD8+ cells induced M1 macrophage
accumulation, impaired glucose tolerance, and insulin
sensitivity in obese mice [86].
Fabbrini et al. showed that adipose tissue from insu-
lin-resistant obese patients had 3- to 10-fold more CD4+ T
cells that produced IL-22 and IL-17 in comparison with
adipose tissue from insulin-sensitive obese and lean
subjects. IL-17 and IL-22 inhibited uptake of glucose
through receptors for IL-22 and IL-17 expressed in the
human liver and skeletal muscle [91].
Treg cells are thought to maintain tolerance/anti-in-
flammatory microenvironment through IL-10 production.
Tregs are abundant in visceral adipose tissue of lean mice,
but their number is significantly reduced in insulin-resis-
tant mice models of obesity [87]; similarly, a reduced
number of Foxp3+ Treg cells was found in visceral
adipose tissue from obese humans [89]. The signal
transducer and activator of transcription 3 (STAT3) plays
an important role in the Th1/Treg balance within the
adipose tissue. STAT3 activity is increased in visceral
adipose tissue of obese mice and is also associated with
increased IL-6 production, an inhibitor of Treg function.
Ablat ion of STAT3 suppresses adipose t issue
inflammation, increases the ratio of Treg/Th1 cells, and
promoted M2 macrophage accumulation [92]. It has
recently been found that Tregs express the insulin
receptor and that stimulation with high levels of insulin
induces a decrease in their IL-10 production through
activation of AKT signaling, thus contributing to obesity-
associated inflammation. Moreover, the hyperinsulinemic
mice fed with a high-fat diet showed a significant decrease
in visceral adipose tissue Tregs IL-10 production and an
increase in IFN-γ production [93]. Lifestyle, nutritional,
and pharmacological interventions aimed at restoring
insulin sensitivity may also restore the Treg function in
obese patients.
Interestingly, Poutahidis T. et al [94] found an asso-
ciation between western diet-associated obesity, type of gut
microflora, and CD4+ Th17 prevalent T cell phenotype.
Display of proinflammatory immune cell profile was
prevented by microbial targeting that induced Foxp3+
regulatory T cells and IL-10. Taken together, these
findings support interventions aimed to enhance the anti-
inflammatory properties of Tregs in humans and reduce the
development of obesity-associated inflammation.
A novel subset of T helper cells, Th22 has been linked
to chronic inflammatory conditions including obesity and
diabetes. The proportion of circulating Th22 cells is in-
creased in overweight/obese patients. Consistent with this
observation, serum IL-22 level was significantly increased
in obese patients when compared with lean subjects. The
development of diabetes within the obese patient popula-
tion led to further increase in circulating Th22 cells and IL-
22 [95] emphasizing the potential association between
Th22 and the pathogenesis of obesity and type 2 diabetes.
NOVELTRIGGERS OFADIPOSE TISSUE
IMMUNE RESPONSE
Aryl Hydrocarbon Receptor Agonists
The rapid increase in the number of people with
obesity and obesity-induced chronic inflammatory diseases
is now attributed to intricate cross talk between genetic
makeup and so termed environmental “obesogens” [96].
Among these, more than 20 chemicals have been shown to
cause long-term weight gain based on exposures during
critical periods of development. Smoking and nicotine,
persistent organophosphate pesticides, flame retardants,
plasticizers and plastics, and fungicides, for example, have
all been linked to obesity in animals. These highly lipo-
philic toxicants have very long half-lives that allow them to
accumulate in the food chain. Western style diet, based on
high consumption of animal fat, increases human exposure
to these ubiquitous toxicants. The dioxin and dioxin-like
pollutants are among the most dangerous. Due to their long
half-life and lipophilicity, they accumulate in adipocytes
and participate in the pathophysiology of obesity and obe-
sity-associated chronic inflammatory diseases [97, 98]
through activation of the aryl hydrocarbon receptor
(AhR) [99, 100]. AhR is a ligand-activated transcription
factor with important roles not only in the xenobiotic
metabolism but in developmental and normal physiology
as well. This particular receptor is ubiquitously present in
adipocytes and, most importantly, in all the cells that par-
ticipate in the immune system responses [101, 102]. More-
over, the preadipocytes that differentiate into mature adi-
pocytes in the presence of even low levels of these toxic
AhR ligands produce significantly more inflammatory cy-
tokines such as TNF-α, IL-6, and chemokine MCP-1
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[103]. Long-term exposure of mice to dioxin-like AhR
agonists led to increased visceral adipose tissue mass,
ectopic fat deposition in the liver (hepatic steatosis) and
peritoneal cavity, and abnormal serum lipid profile similar
with the metabolic syndrome [98]. Importantly, under the
same treatment, AhR KO mice appear resistant to obesity
and its metabolic consequences. Consistent with these
observations, ApoE−/−mice that received dioxin-like
PCBs (AhR agonists) developed atherosclerosis, as
early event in the pathogenesis of abdominal aortic
aneurysms (AAAs) [98].
Inflammation plays an important role in the develop-
ment of atherosclerotic lesions and aortic aneurysms. Pro-
inflammatory cytokines can be released systemically or
produced locally within the endothelium, aortic wall, or,
more importantly, in the inflamed periaortic fat. In a mouse
model of angiotensin-induced AAA, obese ApoE−/−mice
had higher expression of MCP-1 and macrophage
infiltration in the perianeurysmal fat tissue when
compared with lean ones [104]. Collectively, in vivo
studies showed that dioxin-like compounds increase
expression of proinflammatory cytokine TNF-α,
chemokine KC (CXCL1), and MCP-1 within adipocytes
in the inflamed perianeurysmal adipose tissue.
Obesity is associated with migration of bone
marrow-derived macrophages into the visceral adi-
pose tissue where they acquire an M1 (classical ac-
tivation) phenotype and secrete proinflammatory cy-
tokines such as IL-1, IL-6, and TNF-α [105]. Mice
exposed to dioxin-like toxicants presented a signifi-
cant increase in CD68+ cells in the aneurismal sac
and surrounding fat tissue consistent with a
macrophage infiltrate [104]. On the other hand,
AhR pathway is involved in the activation of the
RAS. Infusion of angiotensin II induces aneurysm
formation in mice prone to atherosclerosis (i.e.,
ApoE−/−, LDL−/−). Adding dioxin-like toxicants
(PCBs) to the angiotensin II infusion increased the
incidence and severity of the aneurysms and had an
additive effect, proportional with the visceral fat
mass. This effect is maintained by downregulating
the production of the anti-inflammatory adiponectin.
This adipokine secretion decreases with the increased
body mass, contributing to the chronicity of the
adipose tissue inflammatory process.
Uremic Toxins
CKD is prevalent in the general population.
CKD is associated with adverse outcomes such as
cardiovascular mortality and morbidity. Diabetes and
obesity are some of the main factors associated with
higher risk of CKD. Recently, it has been shown that
the circulating levels of MCP-1 are higher even in
“healthy” obese individuals with an apparently unaf-
fected renal function than those in normal weight
control subjects. This situation is especially critical
due to the association between plasma level of MCP-
1 and of cystatin C, as well as a correlation between
urinary MCP-1 and creatine-to-cystatin ratio, indicat-
ing the existence of a subtle, early kidney injury in
otherwise healthy obese individuals [106]. Mounting
evidence supports a strong association between in-
creased body weight and CKD and its progression
to end-stage renal failure. Excessive caloric and pro-
tein intake has long been considered to facilitate
kidney failure in individuals with CKD. Indoxyl sul-
fate (IS) and p-cresyl sulfate (PCS) are two novel
toxins solely produced by degradation of dietary ty-
rosine, phenylalanine, and tryptophan by the gut mi-
crobiota and further metabolized in the liver that are
present in high concentrations in CKD patients. IS
and PCS are gut-generated uremic toxins that circu-
late predominantly bound to albumin. They associate
with a systemic inflammatory milieu (high serum IL-
6, TNF-α, IFN-γ). They are difficult to remove by
dialysis, and their free fraction accumulates in the
serum proportionally with the CKD stage. Recent
experimental studies have shown that these protein-
bound toxins are involved not only in the progression
of CKD but also in the aggravation of cardiovascular
disease [107]. While PCS had proinflammatory ef-
fects on nonstimulated leukocytes in vitro and con-
tributed to vascular damages, IS inhibited endothelial
cell repair through induction of reactive oxygen spe-
cies (ROS) and activation of the NF-kB pathway
[108]. Moreover, IS can upregulate expression of
MCP-1 and tissue factor in endothelial cells and
macrophages through activation of the AhR, a xeno-
biotic sensor that mediates adaptive and toxic re-
sponses in cells [109]. Increasing premorbidity due
to obesity and insulin resistance coupled with gut
western dietary intake substrate will reverberate in
an increase gut-derived toxins and endobiotics. On
the other hand, chronic exposure to dioxin-like pol-
lutants (AhR ligands) through a high-fat diet and
their accumulation in the adipose tissue will also play
an important role in the overproduction of gut-de-
rived toxins, contributing to the increased cardiovas-
cular risk in CKD patients [110] (Fig. 1).





AAA is defined as an aortic dilation of 3.0 cm
or more in either anteroposterior or transverse planes
[111]. In many cases, AAA rupture may be the first
clinical manifestation of the abdominal aorta pathol-
ogy. Ruptured AAA carries a mortality risk of 70 %
among patients that reach the hospital. Although it is
very well known that smoking, advanced age, and
male gender are associated with a higher prevalence
of AAA, the etiology remains uncertain, and recent
evidence points toward an increased role of adipose
tissue immune response [112]. Although the vascular
pathology in AAA patients is believed to develop
through mechanisms distinct from atherosclerosis, it
is many times associated with obesity and obesity-
related conditions.
We analyzed a cohort of 197 consecutive AAA pa-
tients that requested elective surgery for AAA repair be-
tween September 2007 and October 2011 in the Vascular
and Endovascular Surgery Unit at the S. Martino Univer-
sity Hospital, University of Genoa, Italy. Two thirds of
these AAA patients were overweight/obese (47 % were
overweight (BMI 25–29.9 kg/m2) and 19 % were obese
(BMI ≥30 kg/m2)) (Fig. 2a). While only 39 % of our
patients were current smokers, the majority (93 %)
reported smoking over 100 cigarettes in their lifetime. In
these aspects, our data correlate with other studies that
show positive association with increasing years of
smoking and cigarettes smoked, as well as a positive
association of AAA with excess weight. Importantly, a
preferential abdominal localization of visceral fat, rather
than general obesity, may be more relevant to the etiology
of AAA [113] as waist circumference (WC) and waist-to-
hip ratio (WHR) were found in several studies to have a
significant positive association with AAA [114]. Locally,
the perivascular and perianeurysmal adipose tissues have
been shown to affect inflammation, formation, and severity
of experimental AAA in animals [104, 115–117]. In a
study that included 48,850 men and 39,227 women,
Stackelberg et al. concluded that individuals with an
increased WC (>100 cm for men and >88 cm for
women) had a 30 % higher risk of AAA compared with
those with a normal WC. Moreover, the intra-abdominal
fat assessed by WC correlated with periaortic adipose
tissue mass [118]. Total adiposity expressed as BMI had
no significant correlation with the AAA incidence and
progression. Interestingly, the AAA diameter
decreased with weight loss in mice, limiting the
AAA progression [104].
Mechanistically, the enlarged periaortic adipose tissue
produces proinflammatory cytokines such as IL-6, IL-8,
and MCP-1 that aggravate vascular inflammation, while
the secretion of anti-inflammatory adiponectin is markedly
reduced. High-fat feeding will further reduce the secretion
of adiponectin in human perivascular adipocyte, while
upregulating several proinflammatory gene expression
[119, 120]. This is an important stage of the inflammatory
process because adiponectin is an endogenous modulator
of vascular remodeling proven to abolish proliferation and
Fig. 2. High prevalence of overweight and obesity in patient populations with chronic inflammatory conditions. Obesity has become a worldwide epidemic.
Over two thirds of patients diagnosed with chronic conditions such as inflammatory bowel diseases, cardiorenal syndrome, or abdominal aortic aneurysm in
our clinics during the last 2 years were overweight or obese.
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migration of human vascular smooth muscle cells
(hVSMC) [121] by directly binding to platelet-derived
growth factor-BB-binding protein (PDGF-BB) [122].
Adiponectin knockout mice exhibited severe neointimal
thickening and increased proliferation of VSMC in me-
chanically injured arteries and exhibited profound neointi-
mal hyperplasia [123]. In other animal studies, the in-
creased expression of inflammatory cytokines was found
to trigger the infiltration ofmacrophages in the perivascular
adipose tissue followed by increase formation and growth
of AAA. Ohashi et al. showed that adiponectin modulates
macrophage polarization toward the alternatively activated
M2 cells. Macrophages collected from adiponectin knock-
out mice displayed increased M1 markers (TNF-α, IL-6,
andMCP-1) and decreasedM2markers (IL-10, arginase-1,
and macrophage galactose N-acetyl-galactosamine-specif-
ic lectin-1). Macrophages from both wild-type and
adiponectin knockout mice switched their polarization to-
ward M2 activation after overexpressing the adiponectin.
Monocyte-derived macrophages isolated from human
adipose tissue behaved the same after treatment with
recombinant adiponectin promoting the anti-inflam-
matory phenotype [124].
Moreover, Kent et al. showed that over 55 % of AAA
patients followed by his team had a diet poor in fruit,
vegetables, and nuts but rich in fat and processed meats
(western diet) [112]. This is an important aspect since
organic pollutants are persistent, lipophilic, and
bioaccumulate in the food chain. High-fat foods and highly
processed fatty meats are the main ways of human chronic
exposure to these toxicants followed by accumulation in
human adipose tissue. An increased concentration of per-
sistent organic pollutants in the visceral fat as well as in
perianeurysmal fat has been shown to contribute to the
AAA incidence and growth in animal studies [98]. In
humans, bariatric surgery is used to limit the amount of
ingested food. Patients that underwent bariatric surgery
show restoration of perivascular adipose tissue
vasodilatory capacity, reduction of perivascular inflamma-
tion, and oxidative stress with improved adiponectin and
nitric oxide bioavailability in the perivascular adipose tis-
sue [125].
Cardiorenal Syndrome
Cardiorenal syndrome (CRS) represents a complex
cluster of conditions and clinical presentations of com-
bined heart and kidney disorders. Direct and indirect ef-
fects of each organ that is dysfunctional can initiate and
perpetuate the combined disorder of the two organs
through a complex combination of neurohormonal feed-
back mechanisms [126]. An effective classification of the
CRS was proposed by the Italian nephrologist Claudio
Ronco in 2008. CKD patients with increased plasma levels
of high sensitivity C-reactive protein (hs-CRP), IS, PCS, or
serum amyloid A protein have a higher rate of cardiovas-
cular events. Overweight patients with heart failure (HF)
are ideal candidates to develop CRS and to suffer from
local and systemic inflammation. Excess body weight has
been associated with elevated systemic inflammatory
markers, such as hs-CRP or IL-6 that contribute to tubular
lipid accumulation and pervasive inflammation character-
istic to CKD [127, 128]. In other studies, obesity itself was
an independent risk factor for the development of CKD
[129]. The interaction between obesity and other renal
disease-promoting factors has been partly elucidated
through several observational and mechanistical studies.
One of the potential mechanisms by which obesity pro-
motes CKD is through hyperfiltration-related maladaptive
mechanisms. In one study [130], investigators phenotyped
1,572 young men for various metabolic risk factors. Renal
function was ascertained by calculating creatinine clear-
ance (Cockcroft–Gault equation). The early renal function-
al abnormalities were associated with adiposity (elevated
leptin levels and high BMI) and blood pressure. Increased
adiposity, and in particular abdominal visceral fat, led to an
enhanced production of inflammatory adipokines and glo-
merular hyperfiltration early in the disease. In addition, the
pro-oxidant and proinflammatory state that accompanies
insulin resistance in overweight and obese patients with
CRSmay trigger activation of the RAS and further increase
the proinflammatory molecules produced by the liver and
by the adipose tissue [131, 132]. Studies in obese angio-
tensin receptor 1a knockout (AT1a-KO) mice fed with a
high-fat diet showed increased visceral fat and kidney
macrophage infiltration with a prevalent proinflammatory
M1 phenotype. The obese AT1a-KO presented increased
mesangial expansion, tubular vacuolization, and downreg-
ulated M2 macrophage markers compared with lean mice.
Treatment with AT1 receptor blocker abolished renal mac-
rophage infiltration and switched the macrophage polari-
zation toward the M2 anti-inflammatory and reparatory
macrophage phenotype [133].
Starting from September 2010 to October 2011, we
collected data from 104 male patients with stable chronic
HF NYHA class I–II–III with ejection fraction ≤45 % at
the time of their first visit in the outpatient congestive heart
clinic at S.Martino University Hospital, Genoa, Italy. Sixty
percent (60 %) of our male patient cohort with CRS were
overweight or obese (45 and 15 % respectively, Fig. 2b).
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Out of 104 patients, 93 were former smokers and 11
patients were current smokers. As far as renal dam-
age, 35 % had mild (CKD II), 45 % had moderate
(CKD III), and 7 % had severe (CKD IV) decreases
in the glomerular filtration rate (GFR). Higher BMI
correlated to decreased eGFR (Pearson correlation
coefficient r=0.267 and p=0.025). In addition, higher
BMI correlated with higher values of circulating uric
acid (r=0.277, p=0.033). Our data correlate with
other studies showing that tissue injury in both kid-
ney and HF in the context of obesity has immune-
mediated inflammatory consequences that can accel-
erate remote organ dysfunction.
Inflammatory Bowel Diseases
Crohn’s disease pathogenesis as an inflammatory
bowel disease (IBD) is considered to be an inappropriate
immune response to the luminal bacteria. Although a pri-
mary epithelial defect is believed to set in motion the innate
and acquired arms of the immune system, a signature
feature of Crohn’s disease is the development ofmesenteric
fat inflammation. Macroscopically, the fat tissue wraps
around the diseased bowel segments, enveloping them in
so called “creeping fat.”Given the transmural nature of the
inflammation in IBD, the mesenteric fat inflammation has
generally been considered a secondary event. We collected
anthropometric data from 634 consecutive IBD patients
seen in the Inflammatory Bowel Diseases Center at The
Ohio State University, USA. Sixty-three percent (63 %) of
them were overweight and obese (45 and 18 %, respec-
tively) while only 37 % had a normal body weight
(Fig. 2c). Our data, as well as other recent epidemiological
studies, show an increase incidence of Crohn’s disease
patients that are overweight and obese [134]. Due to the
intimal involvement of the mesenteric fat to the intestinal
inflammation present in IBD, it is reasonable to assume
that adiposity plays an important role in initiating and
perpetuating intestinal inflammation. Emerging data from
multiple medical fields clearly demonstrate that adipocytes
and resident adipose tissue macrophages function as bac-
terial sensors and participate firsthand in the inflammatory
process. Moreover, both macrophages and adipocytes
share regulatory pathways relevant to metabolism and
innate immunity [135]. The small intestine is able to adapt
its lipid absorption capacity to the fat content of the diet
connecting the intestinal lipid metabolism with the suscep-
tibility to obesity [136]. Excess body weight is associ-
ated with systemic microinflammation, and adipose
tissue is a known source of proinflammatory
cytokines (angiotensin, TNF-α, IL-6) [137]. The ex-
panded, inflamed “creeping fat” can thus become a
source of inflammatory mediators at the expense of
the anti-inflammatory adipokine and adiponectin. Sig-
naling through adiponectin receptors regulates over-
lapping pathways responsible for energy balance, in-
sulin sensitivity, and macrophage polarization. Over-
expression of adiponectin or treatment with an
adiponectin agonist can protect mice from experimen-
tal colitis [138, 139] linking adiponectin levels with
inflammation. Moreover, overactivation of the envi-
ronmental sensor—AhR—was associated with worse
colitis and a low ratio of adiponectin to angiotensin.
The opposite was noted in AhR heterozygote mice
[140] that have approximately half the AhR tissue
abundance. Targeted weight loss or dietary interven-
tions could increase HMW adiponectin in IBD pa-
tients and decrease inflammation. On the other hand,
smoking cessation and diets low in fat and processed
meats may decrease exposure to dioxin-like toxins
with beneficial effects on mucosal and mesenteric
fat inflammation.
Visceral adiposity may play an extended role in
the initiation and perpetuation of inflammation in
Crohn’s disease patients with cardiovascular comor-
bidities [134]. Looking in detail to the link between
IBD and coronary artery disease, Gandhi recently
reported that the presence of elevated markers of
systemic inflammation predicted coronary events in
IBD population [141]. Thus, due to their established
pathogenic role for promoting vascular damage [142],
circulating levels of markers of inflammation such as
hs-CRP are likely to predict coronary artery disease
in IBD patients.
POTENTIAL STRATEGIES TO MODULATE
ADIPOSE TISSUE INFLAMMATION
Traditionally, treatment for obesity can include diet,
physical exercise, and pharmaceutical or surgical interven-
tions [32]. Nevertheless, novel strategies should focus on
reducing the adipose tissue inflammatory status before
dieting and exercising as this approach might accelerate
weight loss and increase patient compliance. Already
available PPARγ agonists promote the development of
small size, insulin-sensitive adipocytes although there is
an initial increase in the volume of adipose tissue. Further-
more, PPARγ agonists promote the M2 macrophage po-
larization and stimulate the smaller, insulin-sensitive
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adipocytes to secrete adiponectin, thus reversing the in-
flammatory milieu [143]. Decreasing adipocyte size and
reducing periorgan fat deposition will further help normal-
ize adiponectin secretion [31]. Higher circulating levels of
adiponectin have a significant impact on adipose tissue
macrophage polarization, favoring the M2 anti-inflamma-
tory and reparative phenotype [138].
Dual compounds like ARB/PPAR ligands (i.e.,
telmisartan and irbesartan) can selectively block angioten-
sin II type 1 receptor (AT1) [144] while selectively modu-
lating PPAR. Both actions suppress inflammatory mol-
ecules, oxidative stress, decrease visceral fat accumu-
lation, and augment adiponectin and leptin activities
[40] In addition, this treatment will reduce fibrosis
and preserve endothelial function while improving
vascular and cardiac functions [145].
High-fat diet, smoking, and pollution can be
blamed for adipose tissue becoming a repository of
lipophilic toxic compounds [123]. It is therefore con-
ceivable that surgically reducing the fat mass can sig-
nificantly decrease the amount of toxic and lipophilic
body burden and correct the immune and metabolic
imbalances. In addition, dietary intervention with
AhR ligands from cruciferous vegetables may block
the effect of these toxins through competitive binding
of this receptor.
Serum concentration of uremic toxins depends
on the dietary intake, GFR, and tubular secretion.
Factors promoting generation and absorption include
an increased ratio of dietary protein to carbohy-
drates, an insufficient intake of fibers, and/or re-
duced intestinal protein assimilation as well as
prolonged colonic transit time. Studies with prebiot-
ic and/or probiotic therapies targeting intestinal pro-
duction of IS and PCS modulated toxins production
and absorption by decreasing the intestinal bacterial
growth and metabolism in patients with CKD. In-
gestion of a proportionally higher alkaline diet (e.g.,
a more vegetarian diet), low animal protein ingestion
and, hence, purine intake could proportionally lower
serum uric acid levels.
On the other hand, binding therapies can neu-
tralize toxic precursors and block their intestinal ab-
sorption [146, 147]. For example, AST-120, an orally
ingested activated charcoal adsorbent of uremic
toxins, has been used with success in halting CKD
progression. In human studies, AST-120 treatment
preserved renal function in patients with early stage
of CKD and type 2 diabetes and delayed progression
to end-stage renal disease. Overall, early treatment of
CKD patients with AST-120 resulted in a significant
reduction of CV events [148, 149]. Another strategy
that might be employed to reduce uremia could be
modulation of the AhR-signaling pathway since the
uremic toxin IS is also a potent activator of AhR
[150].
Reports from the Framingham Heart study in-
vestigator showed that vitamin D deficiency is
strongly associated with visceral adiposity [151].
Supplementation with oral calcium and vitamin D
(orange juice) favors weight loss and a beneficial
reduction in the visceral adipose tissue in overweight
and obese adults [152]. This antilipolytic effect might
be due to the increased intracellular calcium, de-
creased intracellular cAMP level, downregulated hor-
mone-sensitive lipase (HSL), and adipose triglyceride
lipase (ATGL) protein expression in adipocytes. In
addition, several studies show that dietary intake of
calcium and vitamin D is inversely associated with
visceral adipocyte size and that higher consumption
of foods that are enriched in calcium and vitamin D
might help reduce the visceral adipose tissue mass
and the associated metabolic disturbances.
CONCLUDING REMARKS
There are new and viable dietary and pharma-
ceutical interventions that can be deployed to reduce
the cardiovascular risk when amplified by adipose
tissue inflammation. Fortunately, current methods
that gauge and quantify adipose tissue are well
established and accessible to every cardiovascular
patient [153]. This review brings in the limelight
several anti-inflammatory agents and interventions
that are currently in clinical trials or yet to be moved
from the researcher bench to the patient bed. New
approaches, such as using adiponectin agonists,
PPARγ agonists, dual ARBs/PPARs, and dietary
modulators of the AhR in addition to a healthy diet
and exercise, could rapidly reduce the adipose tissue
inflammation. More studies are imperatively neces-
sary to clearly define the patient populations who
will benefit from these new therapies.
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